The coronavirus just will not die.
In fact, it’s only getting worse – again.
According to The Hill, “The daily number of new COVID-19 cases in the U.S. is the highest it has been since the height of the pandemic two months ago, as several states around the country experience spikes in cases.”
While panic is forcing markets lower, there are opportunities to be well aware of.
Alpha Pro Tech (APT) just doubled, as some states order the use of face masks. California Gov. Gavin Newson just tweeted, “Californians are now REQUIRED to wear face coverings in public spaces.”
And, according to NPR, Newsom added, “Our numbers are going up, not going down. Hospitalization numbers are just starting to creep back up, and I’m very concerned by what we’re seeing. We think the most impactful thing we can do, short of going back to a stay-at-home order, is wearing face coverings when we can’t practice physical distancing.”
Inovio Pharmaceuticals (INO) is soaring after receiving a $71 million contract from the US Department of Defense to scale up the manufacturing of CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices, which are used to deliver INO-4800 directly into the skin. Dr. J. Joseph Kim, INOVIO’s President and CEO, said, “INOVIO is very pleased to receive this significant funding from the U.S. Department of Defense to continue our rapid scale-up capacity for our breakthrough DNA medicines delivery device CELLECTRA.”
Shares of Moderna Inc. (MRNA) jumped again to $65, and could accelerate higher.
All after MRNA has advanced late-stage development of its coronavirus vaccine. Better, it just finalized the Phase 3 study protocol based on feedback from the U.S. FDA.
The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S. and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Plus, MRNA has completed manufacture of a vaccine required to start the Phase 3 study, and expects dosing in the Phase 3 study to begin in July.
Novavax Inc. (NVAX) is up after being awarded a contract by the U.S. Department of Defense (DoD) for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M adjuvant.
“JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA,” according to a NVAX PR.